Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimotuzumab + toripalimab + nab-paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- Tangdu Hospital
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination regimen is a neoadjuvant therapy consisting of nimotuzumab, toripalimab, nab-paclitaxel, and carboplatin. Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR), inhibiting downstream signaling pathways involved in tumor growth and survival. Toripalimab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, enhancing the immune system's ability to detect and destroy cancer cells. Nab-paclitaxel is an albumin-bound nanoparticle formulation of paclitaxel that inhibits microtubule dynamics, while carboplatin is a platinum-based chemotherapeutic agent that causes DNA cross-linking. This multi-modal approach is being evaluated by Tang-Du Hospital as a neoadjuvant treatment for patients with resectable locally advanced tonsillar squamous cell carcinoma to improve surgical feasibility and clinical outcomes.
- Brand names
- TuoyiTheraCIMAbraxane
- Other names
- Neoadjuvant Nimotuzumab, Toripalimab, and ChemotherapyNimotuzumab + Toripalimab + Nab-paclitaxel + Carboplatin
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)PDCD1 (Programmed cell death protein 1 receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nimotuzumab + toripalimab + nab-paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimotuzumab + toripalimab + nab-paclitaxel + carboplatin.